Evaluation of an optimized [18F]fluoro-deoxy-glucose positron emission tomography voxel-wise method to early support differential diagnosis in atypical Parkinsonian disorders

European Journal of Neurology

Volumn 24, Issue 5, 2017, Pages

  Caminiti, S P ^a,b   Alongi, P ^b   Majno, L ^a   Volonte M A ^b   Cerami, C ^b   Gianolli, L ^b   Comi, G ^b   Perani, D ^a,b  

^a VITA SALUTE SAN RAFFAELE UNIVERSITY   (Italy)

^b SAN RAFFAELE HOSPITAL   (Italy)

Author keywords

biomarkers; corticobasal degeneration; dementia with Lewy bodies; hypometabolism; multiple system atrophy; progressive supranuclear palsy; single subject; Statistical Parametric Mapping

Indexed keywords

FLUORODEOXYGLUCOSE F 18; RADIOPHARMACEUTICAL AGENT;

AGED; ARTICLE; ATYPICAL PARKINSONIAN DISORDER; BRAIN MAPPING; BRAIN METABOLISM; CONTROLLED STUDY; CORTICOBASAL DEGENERATION; DIAGNOSTIC ACCURACY; DIAGNOSTIC TEST ACCURACY STUDY; DIFFERENTIAL DIAGNOSIS; DIFFUSE LEWY BODY DISEASE; DISEASE CLASSIFICATION; EARLY DIAGNOSIS; FEMALE; FOLLOW UP; HUMAN; MAJOR CLINICAL STUDY; MALE; PARAMETRIC TEST; PARKINSONISM; PET SCANNER; POSITRON EMISSION TOMOGRAPHY; PREDICTIVE VALUE; PRIORITY JOURNAL; PROGRESSIVE SUPRANUCLEAR PALSY; RETROSPECTIVE STUDY; SENSITIVITY AND SPECIFICITY; SHY DRAGER SYNDROME; STATISTICAL PARAMETRIC MAPPING; UNCERTAINTY; VOXEL BASED MORPHOMETRY; DEGENERATIVE DISEASE; DIAGNOSTIC IMAGING; EXTRAPYRAMIDAL SYNDROME; METABOLISM; MIDDLE AGED; PROCEDURES; VERY ELDERLY;

AGED; AGED, 80 AND OVER; BASAL GANGLIA DISEASES; DIAGNOSIS, DIFFERENTIAL; FEMALE; FLUORODEOXYGLUCOSE F18; FOLLOW-UP STUDIES; HUMANS; MALE; MIDDLE AGED; NEURODEGENERATIVE DISEASES; PARKINSONIAN DISORDERS; POSITRON-EMISSION TOMOGRAPHY; RADIOPHARMACEUTICALS; RETROSPECTIVE STUDIES; SENSITIVITY AND SPECIFICITY;

EID: 85013968050     PISSN: 13515101     EISSN: 14681331     Source Type: Journal    
DOI: 10.1111/ene.13269     Document Type: Article

References (38)

1. Wenning GK, Litvan I, Tolosa E. Milestones in atypical and secondary parkinsonisms advances in the past 25 years. Mov Disord 2011; 26: 1083–1095.
2. Tolosa E, Wenning G, Poewe W. The diagnosis of Parkinson's disease. Lancet Neurol 2006; 5: 75–86.
3. Joutsa J, Gardberg M, Röyttä M, Kaasinen V. Diagnostic accuracy of parkinsonism syndromes by general neurologists. Parkinsonism Relat Disord 2014; 20: 840–844.
4. Shih LC, Tarsy D. Deep brain stimulation for the treatment of atypical parkinsonism. Mov Disord 2007; 22: 2149–2155.
5. Litvan I, Mangone CA, McKee A, et al. Natural history of progressive supranuclear palsy (Steele-Richardson-Olszewski syndrome) and clinical predictors of survival: a clinicopathological study. J Neurol Neurosurg Psychiatry 1996; 60: 615–620.
6. Wenning GK, Litvan I, Jankovic J, et al. Natural history and survival of 14 patients with corticobasal degeneration confirmed at postmortem examination. J Neurol Neurosurg Psychiatry 1998; 64: 184–189.
7. Litvan I, Grimes DA, Lang AE. Phenotypes and prognosis: clinicopathologic studies of corticobasal degeneration. Adv Neurol 2000; 82: 183.
8. Hughes AJ, Daniel SE, Ben-Shlomo Y, Lees AJ. The accuracy of diagnosis of parkinsonian syndromes in a specialist movement disorder service. Brain 2002; 125: 861–870.
9. Mosconi L. Glucose metabolism in normal aging and Alzheimer's disease: methodological and physiological considerations for PET studies. Clin Transl Imaging 2013; 1: 217–233.
10. Magistretti PJ. Cellular bases of functional brain imaging: insights from neuron-glia metabolic coupling. Brain Res 2000; 886: 108–112.
11. Perani D. FDG PET and cognitive symptoms of dementia. Clin Transl Imaging 2013; 1: 247–260.
12. Teune LK, Bartels AL, De Jong BM, et al. Typical cerebral metabolic patterns in neurodegenerative brain diseases. Mov Disord 2010; 25: 2395–2404.
13. Teune LK, Renken RJ, Mudali D, et al. Validation of parkinsonian disease-related metabolic brain patterns. Mov Disord 2013; 28: 547–551.
14. Meyer PT, Hellwig S. Update on SPECT and PET in parkinsonism - part 1: imaging for differential diagnosis. Curr Opin Neurol 2014; 27: 390–397.
15. McKeith IG, Dickson DW, Lowe J, et al. Diagnosis and management of dementia with Lewy bodies: third report of the DLB Consortium. Neurology 2005; 65: 1863–1872.
16. Gilman S, Wenning GK, Low PA, et al. Second consensus statement on the diagnosis of multiple system atrophy. Neurology 2008; 71: 670–676.
17. Armstrong MJ, Litvan I, Lang AE, et al. Criteria for the diagnosis of corticobasal degeneration. Neurology 2013; 80: 496–503.
18. Juh R, Kim J, Moon D, Choe B, Suh T. Different metabolic patterns analysis of Parkinsonism on the 18F-FDG PET. Eur J Radiol 2004; 51: 223–233.
19. Zhao P, Zhang B, Gao S. 18F-FDG PET study on the idiopathic Parkinson's disease from several parkinsonian-plus syndromes. Parkinsonism Relat Disord 2012; 18(Suppl. 1): S60–S62.
20. Hellwig S, Amtage F, Buchert R, et al. [18 F] FDG-PET is superior to [123 I] IBZM-SPECT for the differential diagnosis of parkinsonism. Neurology 2012; 79: 1314–1322.
21. Tang CC, Poston KL, Eckert T, et al. Differential diagnosis of parkinsonism: a metabolic imaging study using pattern analysis. Lancet Neurol 2010; 9: 149–158.
22. Eckert T, Barnes A, Dhawan V, et al. FDG PET in the differential diagnosis of parkinsonian disorders. NeuroImage 2005; 26: 912–921.
23. Tripathi M, Tang CC, Feigin A, et al. Automated differential diagnosis of early parkinsonism using metabolic brain networks: a validation study. J Nucl Med 2016; 57: 60–66.
24. Tripathi M, Dhawan V, Peng S, et al. Differential diagnosis of parkinsonian syndromes using F-18 fluorodeoxyglucose positron emission tomography. Neuroradiology 2013; 55: 483–492.
25. Perani D, Della Rosa PA, Cerami C, et al. Validation of an optimized SPM procedure for FDG-PET in dementia diagnosis in a clinical setting. Neuroimage Clin 2014; 6: 445–454.
26. Cerami C, Della Rosa PA, Magnani G, et al. Brain metabolic maps in Mild Cognitive Impairment predict heterogeneity of progression to dementia. Neuroimage Clin 2014; 7: 187–194.
27. Perani D, Cerami C, Paola S, et al. Cross-validation of biomarkers to early differential diagnosis and prognosis of dementia in a clinical setting. Eur J Nucl Med Mol Imaging 2015; 43: 499–508.
28. Cerami C, Dodich A, Lettieri G, et al. Different FDG-PET metabolic patterns at single-subject level in the behavioral variant of fronto-temporal dementia. Cortex 2016; 83: 101–112.
29. Della Rosa PA, Cerami C, Gallivanone F, et al. A standardized [18F]-FDG-PET template for spatial normalization in statistical parametric mapping of dementia. Neuroinformatics 2014; 12: 575–593.
30. Cerami C, Della Rosa PA, Magnani G, et al. Brain metabolic maps in Mild Cognitive Impairment predict heterogeneity of progression to dementia. Neuroimage Clin 2015; 7: 187–194.
31. Juh R, Pae C-U, Kim T-S, Lee C-U, Choe B, Suh T. Cerebral glucose metabolism in corticobasal degeneration comparison with progressive supranuclear palsy using statistical mapping analysis. Neurosci Lett 2005; 383: 22–27.
32. Magistretti PJ, Pellerin L, Rothman DL, Shulman RG. Energy on demand. Science 1999; 283: 496–497.
33. Borghammer P. Perfusion and metabolism imaging studies in Parkinson's disease. Dan Med J 2012; 59: 1–24.
34. Teräs M, Tolvanen T, Johansson JJ, Williams JJ, Knuuti J. Performance of the new generation of whole-body PET/CT scanners: discovery STE and Discovery VCT. Eur J Nucl Med Mol Imaging 2007; 34: 1683–1692.
35. Varrone A, Asenbaum S, Vander Borght T, et al. EANM procedure guidelines for PET brain imaging using [18F] FDG, version 2. Eur J Nucl Med Mol Imaging 2009; 36: 2103–2110.
36. Friston KJ, Holmes AP, Worsley KJ, Poline J, Frith CD, Frackowiak RSJ. Statistical parametric maps in functional imaging: a general linear approach. Hum Brain Mapp 1994; 2: 189–210.
37. Beaulieu-Boire I, Lang AE. Behavioral effects of levodopa. Mov Disord 2015; 30: 90–102.
38. Tripathi M, Tang CC, Feigin A, et al. Automated differential diagnosis of early parkinsonism using metabolic brain networks: a validation study. J Nucl Med 2015; 57: 60–66.